Basics Prelude Therapeutics Inc. IPO Date: September 25, 2020 Sector: Healthcare Industry: Biotech Market Cap: $45.15M Activated in VL: True Average Daily Range Avg Daily Range: $0.61 | 4.28% Avg Daily Range (30 D): $0.05 | 5.49% Avg Daily Range (90 D): $0.04 | 4.59% Institutional Daily Volume Avg Daily Volume: .17M Avg Daily Volume (30 D): .08M Avg Daily Volume (90 D): .14M Trade Size Avg Trade Size (Sh.): 105 Avg Trade Size (Sh.) (30 D): 251 Avg Trade Size (Sh.) (90 D): 246 Institutional Trades Total Inst.Trades: 332 Avg Inst. Trade: $1.98M Avg Inst. Trade (30 D): $.73M Avg Inst. Trade (90 D): $.53M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.37M Avg Closing Trade (30 D): $.53M Avg Closing Trade (90 D): $.53M Avg Closing Volume: 79.74K         News Sep 13, 2024 @ 2:00 PM Prelude Therapeutics’ SMARCA2 Degrader PRT3... Source: Prelude Therapeutics Incorporated Jun 3, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Upcoming He... Source: Prelude Therapeutics, Inc. May 9, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Citizens JM... Source: Prelude Therapeutics, Inc. May 7, 2024 @ 11:01 AM Prelude Therapeutics Reports First Quarter 2024 Fi... Source: Prelude Therapeutics, Inc. Apr 9, 2024 @ 8:35 PM Prelude Highlights Continued Strength of Discovery... Source: Prelude Therapeutics, Inc. Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.69 $-.42 $-.38 Diluted EPS $-1.69 $-.42 $-.38 Revenue $ 7M $ M $ 4M Gross Profit $ $ $ Net Income / Loss $ -127.83M $ -32.09M $ -28.73M Operating Income / Loss $ -139.98M $ -34.61M $ -33.83M Cost of Revenue $ $ $ Net Cash Flow $ 15.56M $ 27.8M $ 1.34M PE Ratio